Hydrogen Gas / COX2 Cancer Research Results

H2, Hydrogen Gas: Click to Expand ⟱
Features:
Hydrogen Gas, Powerful Antioxidant
Mechanistically, H₂ is most defensibly framed as a selective antioxidant + anti-inflammatory signaling modulator (often via Nrf2↑ and NF-κB↓ / NLRP3↓), with strongest clinical relevance in oncology being reduction of treatment toxicities (radiation/CCRT side-effects), with mixed/early evidence for direct anticancer effects.

1.Antioxidant and Nrf2/ARE Pathway: activate Nrf2, which induces antioxidant enzymes.
2.NF-κB Pathway: reported to inhibit NF-κB activation, thereby reducing inflammatory cytokine production
3.Mitochondrial Apoptosis Pathway
4.MAPK (Mitogen-Activated Protein Kinases) Pathway
5.PI3K/Akt/mTOR Pathway
6.Inflammatory Cytokine Signaling: Reducing cytokines (such as IL-6, TNF-α)
7.p53 Pathway
8.Autophagy Pathways: might regulate autophagy, (dual roles in cancer)

Example unit sometimes used in studies
Example Canadian Supplier

Hydrogen gas can be generated in small amount by hydrogenase of certain members of the human gastrointestinal tract microbiota from unabsorbed carbohydrates in the intestine through degradation and metabolism, which then is partially diffused into blood flow and released and detected in exhaled breath, indicating its potential to serve as a biomarker.

Many studies have shown that H2 therapy can reduce oxidative stress. This, however, contradicts radiation therapy and chemotherapy, in which ROS are required to induce apoptosis and combat cancer. Yet many studies show chemoprotective and radioprotective and some even show chemosentizing
Nevertheless there are some papers claiming ROS ↑ for cancer cells

Hydrogen Gas in Water is also used.
- the amount of H2 dissolved in solutions is limited: up to 0.8 mM (1.6 mg/L) H2 can be dissolved in water under atmospheric pressure at room temperature

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Selective ROS/RNS buffering (•OH, ONOO− emphasis) Oxidative damage tone ↓ (context-dependent) Radiation/chemo oxidative injury ↓ P, R Rapid cytoprotection Landmark work proposes H2 selectively reduces highly reactive species (e.g., hydroxyl radical) rather than globally suppressing signaling ROS. Treat as "selective antioxidant" rather than broad ROS quencher.
2 Nrf2 antioxidant response (Keap1/Nrf2; SOD/GPx/GSH systems) Stress adaptation modulation (context-dependent) Nrf2 ↑; endogenous antioxidant enzymes ↑ R, G Endogenous antioxidant upshift Multiple reviews describe H2 as engaging Nrf2-linked programs and increasing antioxidant enzyme activity; direction in tumors is model-specific and should not be oversold as uniformly anti-tumor.
3 NF-κB inflammatory transcription Inflammatory/pro-survival transcription ↓ (context) Inflammation ↓ (tissue protective) R, G Anti-inflammatory signaling Commonly reported downstream of redox modulation: reduced NF-κB activity and reduced inflammatory cytokine outputs.
4 NLRP3 inflammasome (priming/activation) Inflammasome signaling ↓ (context) NLRP3 activation ↓; tissue injury signaling ↓ R, G Inflammasome dampening Often described as part of an antioxidant–anti-inflammatory synergy (Nrf2↑ with NF-κB/NLRP3↓). Use "reported" language.
5 Mitochondrial protection / mitochondrial ROS Mito-stress tone ↓ (context) Mitochondrial function preserved; oxidative injury ↓ R, G Bioenergetic stabilization Frequently reported as reduced mitochondrial oxidative injury and improved cellular resilience in injury/inflammation models.
6 Radiation/CCRT toxicity mitigation (clinical relevance) Adjunct use: may reduce acute radiation toxicities without obvious loss of tumor control (early evidence) Mucositis/dermatitis/inflammation severity ↓ (reported) G Supportive care Clinical studies report feasibility/safety and reduced radiotherapy-related toxicities in selected settings; treat as supportive/adjunct, not standalone anti-cancer therapy.
7 Apoptosis / proliferation control Mixed reports: apoptosis ↑ or neutral depending on model Often anti-apoptotic in injury models G Context-dependent cell fate shift Unlike classic cytotoxins, H2 effects on apoptosis/proliferation are not uniform; keep as model-dependent and secondary.
8 Clinical safety signal (inhalation studies) — Generally well tolerated at low concentrations in studied settings — Translation constraint / safety framing Human safety studies exist for low-concentration inhalation; practical use must be medical-grade and safety-controlled due to flammability risk.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (direct chemical/rapid signaling effects)
  • R: 30 min–3 hr (acute redox + inflammatory signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
2503- H2,    Brain Metastases Completely Disappear in Non-Small Cell Lung Cancer Using Hydrogen Gas Inhalation: A Case Report
- Case Report, Lung, NA
TumVol↓, OS↑, Dose↝, Dose↝, CEA↓, CA125↓, CYFRA21-1↓, SIRT1↓, COX2↓, IL1β↓, IL6↓, TNF-α↓, HMGB1↓, NF-kB↓, EP2↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

SIRT1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EP2↓, 1,  

Migration ⓘ

CEA↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   HMGB1↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 2,  

Clinical Biomarkers ⓘ

CA125↓, 1,   CEA↓, 1,   CYFRA21-1↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,   TumVol↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:295  Target#:66  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page